• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia.

作者信息

Lenk Lennart, Winterberg Dorothee, Vogiatzi Fotini, Laqua Anna, Spory Lea, Mayar Ahmad, Dietterle Anna, Münch Gina, Vokuhl Christian, Richter Julia, Polson Andrew G, Schüler Thomas, Kahlert Ulf D, Peipp Matthias, Valerius Thomas, Schrappe Martin, Cario Gunnar, Jumaa Hassan, Hobeika Elias, Brüggemann Monika, Alsadeq Ameera, Schewe Denis M

机构信息

Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.

Department of Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany.

出版信息

Hemasphere. 2022 Jul 15;6(8):e754. doi: 10.1097/HS9.0000000000000754. eCollection 2022 Aug.

DOI:10.1097/HS9.0000000000000754
PMID:35935606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9351922/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1b0/9351922/371427a355bc/hs9-6-e754-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1b0/9351922/0bf95c68841a/hs9-6-e754-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1b0/9351922/371427a355bc/hs9-6-e754-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1b0/9351922/0bf95c68841a/hs9-6-e754-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1b0/9351922/371427a355bc/hs9-6-e754-g002.jpg

相似文献

1
Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia.CD79b免疫疗法治疗B细胞前体急性淋巴细胞白血病疗效的临床前证据
Hemasphere. 2022 Jul 15;6(8):e754. doi: 10.1097/HS9.0000000000000754. eCollection 2022 Aug.
2
Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia.B29（CD79b）和mb-1（CD79a）蛋白在急性淋巴细胞白血病中的差异表达。
Leukemia. 1996 May;10(5):769-73.
3
Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b.基于 TCR 的治疗方法中靶向 BCR 相关蛋白 CD79b 的治疗受到 CD79b 异常表达的阻碍。
Blood. 2015 Feb 5;125(6):949-58. doi: 10.1182/blood-2014-07-587840. Epub 2014 Nov 20.
4
Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia.针对 B 细胞急性淋巴细胞白血病的 CD3/CD19 双特异性和新型 CD3/CD19/CD20 三特异性抗体的临床前特征分析及比较：急性淋巴细胞白血病的靶向免疫治疗。
Front Med. 2022 Feb;16(1):139-149. doi: 10.1007/s11684-021-0835-8. Epub 2021 Aug 31.
5
Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.免疫疗法在前体B细胞急性淋巴细胞白血病中的新作用。
Expert Rev Hematol. 2017 Sep;10(9):783-799. doi: 10.1080/17474086.2017.1350165. Epub 2017 Jul 10.
6
High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.高 CD45 表面表达决定了按照 ALL-BFM 2000 方案治疗的前体 B 细胞和 T 细胞急性淋巴细胞白血病患儿的复发风险。
Haematologica. 2014 Jan;99(1):103-10. doi: 10.3324/haematol.2013.090225. Epub 2013 Aug 2.
7
Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.埃及儿童B细胞急性淋巴细胞白血病细胞遗传学亚组的免疫表型特征
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S19-S24.e1. doi: 10.1016/j.clml.2016.02.032.
8
Alteration of the immune environment in bone marrow from children with recurrent B cell precursor acute lymphoblastic leukemia.儿童复发性 B 细胞前体急性淋巴细胞白血病骨髓免疫环境的改变。
Cancer Sci. 2022 Jan;113(1):41-52. doi: 10.1111/cas.15186. Epub 2021 Nov 29.
9
[Treatment strategy for B cell precursor acute lymphoblastic leukemia in children].[儿童B细胞前体急性淋巴细胞白血病的治疗策略]
Rinsho Ketsueki. 2022;63(7):816-825. doi: 10.11406/rinketsu.63.816.
10
Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.肿瘤抑制因子BTG1和IKZF1在小鼠白血病发展过程中协同作用，并增加B细胞前体急性淋巴细胞白血病患者的复发风险。
Haematologica. 2017 Mar;102(3):541-551. doi: 10.3324/haematol.2016.153023. Epub 2016 Dec 15.

引用本文的文献

1
An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia.一种靶向VpreB1用于治疗B细胞急性淋巴细胞白血病的抗体药物偶联物。
Blood Neoplasia. 2025 May 19;2(3):100120. doi: 10.1016/j.bneo.2025.100120. eCollection 2025 Aug.
2
Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation.白血病治疗中的纳米技术：革新靶向药物递送与免疫调节
Clin Exp Med. 2025 May 17;25(1):166. doi: 10.1007/s10238-025-01686-z.
3
Dynamic evolution of TCF3-PBX1 leukemias at the single-cell level under chemotherapy pressure.

本文引用的文献

1
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.泊洛妥珠单抗联合化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤
N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.
2
VpreB surrogate light chain expression in B-lineage ALL: a report from the Children's Oncology Group.VpreB 替代轻链在 B 细胞急性淋巴细胞白血病中的表达：来自儿童肿瘤学组的报告。
Blood Adv. 2022 Jan 25;6(2):585-589. doi: 10.1182/bloodadvances.2021005245.
3
CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia.
化疗压力下TCF3-PBX1白血病在单细胞水平的动态演变
Hemasphere. 2025 Feb 3;9(2):e70071. doi: 10.1002/hem3.70071. eCollection 2025 Feb.
4
A brain organoid/ALL coculture model reveals the AP-1 pathway as critically associated with CNS involvement of BCP-ALL.脑类器官/急性淋巴细胞白血病共培养模型揭示了 AP-1 通路与 B 细胞型急性淋巴细胞白血病中枢神经系统受累密切相关。
Blood Adv. 2024 Oct 8;8(19):4997-5011. doi: 10.1182/bloodadvances.2023011145.
5
The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis.IL-7R 拮抗剂 lusvertikimab 通过抗体依赖性细胞吞噬作用减少异种移植 ALL 中的白血病负担。
Blood. 2024 Jun 27;143(26):2735-2748. doi: 10.1182/blood.2023021088.
6
Multi-targeted immunotherapeutics to treat B cell malignancies.多靶点免疫疗法治疗 B 细胞恶性肿瘤。
J Control Release. 2023 Jun;358:232-258. doi: 10.1016/j.jconrel.2023.04.048. Epub 2023 May 5.
CD79a 促进小儿 B 细胞前体急性淋巴细胞白血病中枢神经系统浸润和白血病嵌合体形成。
Commun Biol. 2021 Jan 15;4(1):73. doi: 10.1038/s42003-020-01591-z.
4
Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia.达雷妥尤单抗在儿童T细胞急性淋巴细胞白血病的临床前模型中可清除微小残留病。
Blood. 2019 Aug 22;134(8):713-716. doi: 10.1182/blood.2019000904. Epub 2019 Jul 16.
5
IL7R is associated with CNS infiltration and relapse in pediatric B-cell precursor acute lymphoblastic leukemia.白细胞介素7受体与小儿B细胞前体急性淋巴细胞白血病的中枢神经系统浸润及复发相关。
Blood. 2018 Oct 11;132(15):1614-1617. doi: 10.1182/blood-2018-04-844209. Epub 2018 Aug 28.
6
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment.接受blinatumomab治疗后小儿B细胞前体急性淋巴细胞白血病的CD19阴性复发
Blood Cancer J. 2017 Dec 20;7(12):659. doi: 10.1038/s41408-017-0023-x.
7
An Fc-engineered CD19 antibody eradicates MRD in patient-derived -rearranged acute lymphoblastic leukemia xenografts.一种 Fc 工程化的 CD19 抗体可清除源自患者的重排急性淋巴细胞白血病异种移植物中的微小残留病。
Blood. 2017 Sep 28;130(13):1543-1552. doi: 10.1182/blood-2017-01-764316. Epub 2017 Jul 11.
8
AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.AIEOP-BFM 共识指南 2016 年版：儿童急性淋巴细胞白血病流式细胞免疫表型分析
Cytometry B Clin Cytom. 2018 Jan;94(1):82-93. doi: 10.1002/cyto.b.21518. Epub 2017 Feb 21.
9
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.异种移植公共库助力小鼠研究中的发现及类似随机II期试验。
Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008.
10
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia.BCL6与前B细胞受体信号传导之间的自我强化反馈激活定义了急性淋巴细胞白血病的一种独特亚型。
Cancer Cell. 2015 Mar 9;27(3):409-25. doi: 10.1016/j.ccell.2015.02.003.